Nallelyt Segundo-Arizmendi

Dr. Nallelyt Segundo-Arizmendi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2021 in Viruses
Verified
Journal Article
Open access
PDF file
JGJANETH GOMEZ-GARCIA
JANETH GOMEZ-GARCIA
ACAlejandra Chavez-Carbajal
Alejandra Chavez-Carbajal
NSNallelyt Segundo-Arizmendi
Nallelyt Segundo-Arizmendi
MBMiriam Guadalupe Baron
Miriam Guadalupe Baron
SMSusana Mendoza
Susana Mendoza
OTOscar Torres-Angeles
Oscar Torres-Angeles
Modern bacteriophage encapsulation methods based on polymers such as alginate have been developed recently for their use in phage therapy for veterinary purposes. In birds, it has been proven that using this delivery system allows the release of the bacteriophage in the small intestine, the site of infection by Salmonella spp. This work designed an approach for phage therapy using encapsulation by ionotropic gelation of the lytic bacteriophage S1 for Salmonella enterica in 2% w/v alginate beads using 2% w/v calcium chloride as crosslinking agent. This formulation resulted in beads with an average size of 3.73 ± 0.04 mm and an encapsulation efficiency of 70%. In vitro, the beads protected the bacteriophages from pH 3 and released them at higher pH. To confirm that this would protect the bacteriophages from gastrointestinal pH changes, we tested the phage infectivity in vivo assay. Using a model chicken (Gallus gallus domesticus) infected with Salmonella Enteritidis, we confirmed that after 3 h of the beads delivery, infective phages were present in the chicken’s duodenal and caecal sections. This study demonstrates that our phage formulation is an effective system for release and delivery of bacteriophage S1 against Salmonella Enteritidis with potential use in the poultry sector.

7 January 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
NSNallelyt Segundo-Arizmendi
Nallelyt Segundo-Arizmendi
DADafne Arellano-Maciel
Dafne Arellano-Maciel
Abraham Omar RiveraAbraham Omar Rivera
Abraham Omar Rivera
APAdán Manuel Piña-González
Adán Manuel Piña-González
GLGamaliel López-Leal
Gamaliel López-Leal
Efren Hernandez-BaltazarEfren Hernandez-Baltazar
Efren Hernandez-Baltazar
Phage therapy, which involves the use of bacteriophages (phages) to combat bacterial infections, is emerging as a promising approach to address the escalating threat posed by multidrug-resistant (MDR) bacteria. This brief review examines the historical background and recent advancements in phage research, focusing on their genomics, interactions with host bacteria, and progress in medical and biotechnological applications. Additionally, we expose key aspects of the mechanisms of action, and therapeutic uses of phage considerations in treating MDR bacterial infections are discussed, particularly in the context of infections related to virus–bacteria interactions.